On Friday, Phathom Pharmaceuticals Inc (NASDAQ: PHAT) was -5.26% drop from the session before settling in for the closing price of $9.69. A 52-week range for PHAT has been $2.21 – $19.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 12.50% over the past five years. When this article was written, the company’s average yearly earnings per share was at 42.39%. With a float of $37.85 million, this company’s outstanding shares have now reached $69.64 million.
Let’s look at the performance matrix of the company that is accounted for 427 employees. In terms of profitability, gross margin is 86.23%, operating margin of -349.84%, and the pretax margin is -307.2%.
Phathom Pharmaceuticals Inc (PHAT) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Phathom Pharmaceuticals Inc stocks. The insider ownership of Phathom Pharmaceuticals Inc is 45.79%, while institutional ownership is 47.35%. The most recent insider transaction that took place on May 21 ’25, was worth 14,609. In this transaction Director of this company bought 3,780 shares at a rate of $3.86, taking the stock ownership to the 59,403 shares. Before that another transaction happened on May 14 ’25, when Company’s Director bought 6,300 for $3.32, making the entire transaction worth $20,919. This insider now owns 55,623 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 42.39% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
You can see what Phathom Pharmaceuticals Inc (PHAT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.24, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -0.40 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) saw its 5-day average volume 0.88 million, a negative change from its year-to-date volume of 1.93 million. As of the previous 9 days, the stock’s Stochastic %D was 65.07%.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 68.94%, which indicates a significant increase from 41.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.68 in the past 14 days, which was higher than the 0.67 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.53, while its 200-day Moving Average is $8.39. Nevertheless, the first resistance level for the watch stands at $9.53 in the near term. At $9.87, the stock is likely to face the second major resistance level. The third major resistance level sits at $10.05. If the price goes on to break the first support level at $9.01, it is likely to go to the next support level at $8.83. Assuming the price breaks the second support level, the third support level stands at $8.49.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
There are 69,814K outstanding shares of the company, which has a market capitalization of 640.89 million. As of now, sales total 55,250 K while income totals -334,330 K. Its latest quarter income was 28,520 K while its last quarter net income were -94,320 K.
